Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

Limited Competition. Adva-27a targets topoisomerase 2-positive breast cancer

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Scorpion King Member Profile
Followed By 3
Posts 638
Boards Moderated 0
Alias Born 05/24/13
160x600 placeholder
Roche's Spark in Gene-Therapy Collaboration With Senti Bio Dow Jones News - 4/13/2021 10:10:00 AM
Roche unit Spark Therapeutics inks deal to bolster gene therapy research platform Seeking Alpha - 4/13/2021 9:16:17 AM
Novartis, Genentech Get FDA OK of Self-Administered Xolair Dow Jones News - 4/12/2021 2:12:00 PM
Roche's Phase 3 Trial of Casirivimab, Imdevimab Shows Cut Risk of Symptomatic Covid-19 Infections Dow Jones News - 4/12/2021 1:52:00 AM
Roche's Elecsys COVID-19 antibody test now available in Canada Seeking Alpha - 4/6/2021 8:41:03 AM
PTC Therapeutics earns $20M milestone under Evrysdi deal with Roche Seeking Alpha - 4/1/2021 8:34:57 AM
Roche, PTC Therapeutics Gets European OK of Evrysdi in Spinal Muscular Atrophy Dow Jones News - 3/30/2021 6:56:00 AM
iTeos Therapeutics shares rise 4% as Wedbush ups price target Seeking Alpha - 3/25/2021 4:19:31 PM
Ixico Shares Fall as Roche Halts Huntington's Disease Trial Dow Jones News - 3/23/2021 11:59:00 AM
Ionis Pharmaceuticals Partner Stops Dosing in Huntington's Disease Study Dow Jones News - 3/23/2021 7:15:00 AM
Roche Covid-19 Antibody Trial Meets Primary Endpoint Dow Jones News - 3/23/2021 2:50:00 AM
Genentech: Dosing to Stop in Phase III Clinical Study of Tominersen Dow Jones News - 3/22/2021 4:58:00 PM
Ionis announces discontinuation of Huntington's disease studies Seeking Alpha - 3/22/2021 4:39:33 PM
Genentech's Tecentriq meets late-stage lung cancer study main goal Seeking Alpha - 3/22/2021 6:29:16 AM
Roche's Tecentriq Meets Primary Endpoint in Phase 3 Lung Cancer Study Dow Jones News - 3/22/2021 2:45:00 AM
Artelo Biosciences Shares Rise 8% on Acceptance Into U.K Oncology Program Dow Jones News - 3/19/2021 10:49:00 AM
Roche's Phase 3 Trial of Actemra/RoActemra Plus Veklury Didn't Meet Primary Endpoint Dow Jones News - 3/11/2021 1:52:00 AM
Natera and Genentech initiate late-stage muscle-invasive bladder cancer trial Seeking Alpha - 3/10/2021 9:25:11 AM
Correction to Roche Tecentriq Article on Monday Dow Jones News - 3/9/2021 7:17:00 AM
Roche Withdraws Bladder-Cancer Indication for Tecentriq in US Dow Jones News - 3/8/2021 1:59:00 AM
Genentech pulls back U.S. indication for Tecentriq in bladder cancer Seeking Alpha - 3/8/2021 1:28:48 AM
FDA OKs Roche's Actemra injection for regulating pulmonary function in SSc-ILD Seeking Alpha - 3/5/2021 4:48:31 AM
Dicerna: Roche Phase 2 Hepatitis B Trial Triggers $25 Million Milestone Dow Jones News - 3/4/2021 9:30:00 AM
Dicerna and Roche start mid-stage Hepatitis B RG6346 trial Seeking Alpha - 3/4/2021 7:47:19 AM
Roche teams up with Tempest Therapeutics in liver cancer study Seeking Alpha - 3/3/2021 3:54:59 PM
Scorpion King   Sunday, 06/09/13 10:00:19 AM
Re: None
Post # of 252 
Limited Competition. Adva-27a targets topoisomerase 2-positive breast cancer patients, a larger group than HER-2 positive patients. There are currently no FDA-approved products targeting TOP-2 positive patients and few companies working on this class of patients.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences